CorMedix to acquire Heron Therapeutics assets, reports Q3 2026 resultsNov 12Quarterly updateCorMedix Inc.
CorMedix to acquire nearly all of Heron Therapeutics' assets in cash-and-stock dealNov 9M&ACorMedix Inc.Heron Therapeutics, Inc. /De/Updated
Bicara reaches substantial enrollment in HPV-negative head and neck cancer trialNov 9Quarterly updateArriVent BioPharma, Inc.Bicara Therapeutics
Viatris to acquire Pacira BioSciences for $36.50 per share in cashOct 8M&APacira Pharmaceuticals, IncViatris Inc.
Pacira reports Q2 2026 results, updates guidance after iovera° sale to Zimmer BiometAug 4Quarterly updateenekinragene inzadenovecPacira Pharmaceuticals, Inc